Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety
of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus
trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute
Collaborators:
Celgene Corporation Novartis The Methodist Hospital System